Table 1.
Characteristics of articles included in the meta-analysis.
| Author | Year | Cancer | Material | Cut-off value | Region | Endpoint | Patient | CD103+ (%) |
|---|---|---|---|---|---|---|---|---|
| Djenidi22 | 2015 | Non-small cell lung cancer | WS | none (continuous) | all three | OS, DFS | 98 | — |
| Wang16 | 2016 | Breast cancer | TMA | 90th percentile | epithelium | OS | 424 | 43 (10.1) |
| Wang33 | 2015 | Urothelial cell carcinoma | WS | >9cells/HPF | epithelium | OS | 262 | 148 (56.5) |
| Bosmuller34 | 2016 | HGSC | TMA | >1 cell/HPF | epithelium | OS | 202 | 140 (69.3) |
| Santoiemma26 | 2016 | Ovarian cancer | TMA | ≥10 cells/core | epithelium | OS | 135 | 31 (23.0) |
| Koh23 | 2017 | Squamous cell lung cancer | TMA | mean | epithelium/stroma | OS, DFS | 378 | 108/111 (28.6/29.4)a |
| Workel20 | 2016 | Endometrial adenocarcinoma | TMA | >27.28 cells/mm2 | total | DFS, DSS | 253 | 84 (33.2) |
| Komdeur35 | 2017 | Cervical cancer | TMA | >29 cells/mm2 | total | DFS, DSS | 387 | 200 (51.7) |
| Zhou27 | 2018 | Renal cell carcinoma | WS | >1 cell/HPF | total | DSS | 200 | 117 (58.5) |
| Webb36 | 2013 | Ovarian cancer | TMA | ≥5(1) cells/coreb | TMA | DSS | 485 | 339 (69.9) |
*OS: overall survival, DFS: disese-free survival, DSS: disease-specific survival, WS: whole slide, TMA: tissue microarray, HPF: high power field, HGSC: high grade serous ovarian cancer.
aPositive for epithelial area/positive for stromal area.
b≥5 cells/core to evaluate prognosis, ≥1 cell/core to evaluate positivity.